Search in:

Expert Review of Anticancer Therapy Volume 11, 2011 - Issue 11

Submit an article Journal homepage

151

Views

CrossRef citations to date

Altmetric

Clinical Trial Report

Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience

Giuseppe Procopio Fondazione IRCCS ‘Istituto Nazionale Tumori’, Medical Oncology, Via G. Venezian 1, 20133 Milan, Italy;[email protected]

Elena Verzoni Fondazione IRCCS ‘Istituto Nazionale Tumori’, Medical Oncology, Via G. Venezian 1, 20133 Milan, Italy; Fondazione IRCCS ‘Istituto Nazionale Tumori’, Medical Oncology, Via G. Venezian 1, 20133 Milan, Italy

Roberto Iacovelli Fondazione IRCCS ‘Istituto Nazionale Tumori’, Medical Oncology, Via G. Venezian 1, 20133 Milan, Italy; Fondazione IRCCS ‘Istituto Nazionale Tumori’, Medical Oncology, Via G. Venezian 1, 20133 Milan, Italy

Valentina Guadalupi Fondazione IRCCS ‘Istituto Nazionale Tumori’, Medical Oncology, Via G. Venezian 1, 20133 Milan, Italy; Fondazione IRCCS ‘Istituto Nazionale Tumori’, Medical Oncology, Via G. Venezian 1, 20133 Milan, Italy

Francesco Gelsomino Fondazione IRCCS ‘Istituto Nazionale Tumori’, Medical Oncology, Via G. Venezian 1, 20133 Milan, Italy; Fondazione IRCCS ‘Istituto Nazionale Tumori’, Medical Oncology, Via G. Venezian 1, 20133 Milan, Italy

Roberto Buzzoni Fondazione IRCCS ‘Istituto Nazionale Tumori’, Medical Oncology, Via G. Venezian 1, 20133 Milan, Italy; Fondazione IRCCS ‘Istituto Nazionale Tumori’, Medical Oncology, Via G. Venezian 1, 20133 Milan, Italy

Pages 1631-1640 | Published online: 10 Jan 2014

Cite this article
https://doi.org/10.1586/era.11.154

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

References

Lindblad P. Epidemiology of renal cell carcinoma. Scand. J. Surg.93(2), 88–96 (2004).
PubMedGoogle Scholar
Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr. Rising incidence of renal cell cancer in the United States. JAMA281(17), 1628–1631 (1999).
PubMed Web of Science ®Google Scholar
Bos SD, Mellema CT, Mensink HJ. Increase in incidental renal cell carcinoma in the northern part of The Netherlands. Eur. Urol.37(3), 267–270 (2000).
PubMed Web of Science ®Google Scholar
Mevorach RA, Segal AJ, Tersegno ME, Frank IN. Renal cell carcinoma: incidental diagnosis and natural history: review of 235 cases. Urology39(6), 519–522 (1992).
PubMed Web of Science ®Google Scholar
Hock LM, Lynch J, Balaji KC. Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of surveillance, epidemiology and end results program data. J. Urol.167(1), 57–60 (2002).
PubMed Web of Science ®Google Scholar
Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J. Urol.166(5), 1611–1623 (2001).
PubMed Web of Science ®Google Scholar
Atzpodien J, Royston P, Wandert T, Reitz M. Metastatic renal carcinoma comprehensive prognostic system. Br. J. Cancer88(3), 348–353 (2003).
PubMed Web of Science ®Google Scholar
Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am. J. Surg. Pathol.27(5), 612–624 (2003).
PubMed Web of Science ®Google Scholar
Jemal A, Tiwari RC, Murray T et al. Cancer statistics, 2004. CA Cancer. J. Clin.54(1), 8–29 (2004).
PubMed Web of Science ®Google Scholar
Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J. Urol.163(2), 408–417 (2003).
Google Scholar
Oudard S, George D, Medioni J et al. Treatment options in renal cell carcinoma: past, present and future. Ann. Oncol.18(Suppl. 10), 25–31 (2007).
PubMed Web of Science ®Google Scholar
Atkins MB, Regan M, McDermott D. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin. Cancer. Res.10(Suppl.), 6342–6346 (2004).
PubMed Web of Science ®Google Scholar
Hutson TE. Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Clinical Evidence. The Oncologist16(Suppl. 2), 14–22 (2011).
PubMed Web of Science ®Google Scholar
Dudek AZ, Zolnierek J, Dham A, Lindgren BR, Szczylik C. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer115(1), 61–67 (2009).
PubMed Web of Science ®Google Scholar
Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled Phase III trial. Lancet372(9637), 449–456 (2008).
PubMed Web of Science ®Google Scholar
Hutson TE, Bukowski RM, Cowey CL, Figlin R, Escudier B, Sternberg CN. Sequential use of targeted agents in the treatment of renal cell carcinoma. Crit. Rev. Oncol. Hematol.77(1), 48–62 (2011).
PubMed Web of Science ®Google Scholar
Beck J, Procopio G, Bajetta E et al. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. Ann. Oncol.22(8), 1812–1823 (2011).
PubMed Web of Science ®Google Scholar
Grünwald V, Heinzer H, Fiedler W. Managing side effects of angiogenesis inhibitors in RCC. Onkologie30, 519–524 (2007).
PubMedGoogle Scholar
Ivanyi P, Winkler T, Ganser A, Reuter C, Grünwald V. Novel therapies in advanced renal cell carcinoma: management of adverse events from sorafenib and sunitinib. Dtsch. Arztebl. Int.105(13), 232–237 (2008).
Google Scholar
Procopio G,Verzoni E, Guadalupi V et al. Sequential use of sorafenib (So) followed by sunitinib (Su) in metastatic renal cell cancer (mRCC): a single-institution experience [abstract]. Presented at: Genitourinary Cancers Symposium. Orlando, FL, USA, 26–28 February 2009 (Abstract 319).
Google Scholar
Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol.17(8), 2530–2540 (1999).
PubMed Web of Science ®Google Scholar
Silverman SL. From randomized controlled trials to observational studies. Am. J. Med.122(2), 114–120 (2009).
PubMed Web of Science ®Google Scholar
Porta C, Paglino C, Cartenì G et al. Sequencing tyrosine kinase inhibitors or immediately switching to mTOR inhibitors in advanced kidney cancer: a critical review. EJCMO (2011) (In Press).
Google Scholar
Eichelberg C, Heuer R, Chun FK et al. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur. Urol.54(6), 1373–1378 (2008).
PubMed Web of Science ®Google Scholar
Sablin MP, Negrier S, Ravaud A et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J. Urol.182, 29–34 (2009).
PubMed Web of Science ®Google Scholar
Zimmerman K, Schmittel A, Steiner U et al. Sunitinib treatment for patients with advanced clear cell renal-cell carcinoma after progression on sorafenib. Oncology76(5), 350–354 (2009).
Google Scholar
Garcia JA, Hutson TE, Elson P et al. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. Cancer116(23), 5383–5390 (2010).
PubMed Web of Science ®Google Scholar

Websites

NCCN Clinical Practice Guidelines in Oncology™Kidney Cancer. Version 2.2010. ©2009 National Comprehensive Cancer Network, Inc www.nccn.org/professionals/physician_gls/f_guidelines.asp#site (Accessed 20 March 2011)
Google Scholar
ClinicalTrials.gov. NCT00631371. Study Comparing Bevacizumab + Temsirolimus vs Bevacizumab + Interferon-Alfa in Advanced Renal Cell Carcinoma Subjects (INTORACT) www.clinicaltrials.gov/ct2/show/NCT00631371?term=NCT00631371&rank=1 (Accessed 22 March 2011)
Google Scholar
ClinicalTrials.gov. NCT00378703. Bevacizumab, Sorafenib, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer www.clinicaltrials.gov/ct2/show/NCT00378703?term=NCT00378703&rank=1 (Accessed 22 March 2011)
Google Scholar
ClinicalTrials.gov. NCT00619268. Combination of Temsirolimus and Bevacizumab in Patients with Metastatic Renal Cell Carcinoma (TORAVA) www.clinicaltrials.gov/ct2/show/NCT00619268?term=NCT00619268&rank=1 (Accessed 22 March 2011)
Google Scholar
ClinicalTrials.gov. NCT00719264. Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab in Adult Patients With Kidney Cancer www.clinicaltrials.gov/ct2/show/NCT00719264?term=NCT00719264&rank=1 (Accessed 22 March 2011)
Google Scholar
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Kidney Cancer. V. 2.2010 www.nccn.org/professionals/physician_gls/PDF/kidney.pdf (Accessed 22 March 2011)
Google Scholar
Ljungberg B, Cowan N, Hanbury DC et al. European Association of Urology Guidelines on Renal Cell Carcinoma (2010) www.uroweb.org/gls/pdf/Renal%20Cell%20Carcinoma%202010.pdf (Accessed 22 March 2011)
Google Scholar
ClinicalTrials.gov. NCT00732914. A Phase III Randomized Sequential Open-Label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Sunitinib Versus Sunitinib Followed by Sorafenib in the Treatment of First-Line Advanced/Metastatic Renal Cell Carcinoma http://clinicaltrials.gov/ct2/show/NCT00732914 (Accessed 22 March 2011)
Google Scholar
Common Terminology Criteria for Adverse Events v3.0 (CTCAE) http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf (Accessed 22 March 2011)
Google Scholar
ClinicalTrials.gov http://clinicaltrials.gov/ct2/show/NCT00930033 (Accessed 25 August 2011)
Google Scholar
EORTC protocol 30073 – SURTIME www.eortc.be/protoc/details.asp?protocol=30073 (Accessed 25 August 2011)
Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience

References

Websites

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience

References

Websites

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date